BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25844600)

  • 21. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
    Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
    J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
    Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
    Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
    Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
    Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation.
    Zhou Z; Zalutsky MR; Chitneni SK
    Mol Pharm; 2021 Oct; 18(10):3871-3881. PubMed ID: 34523337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 Inhibition.
    Lebraud H; Noble RA; Phillips N; Heam K; Castro J; Zhao Y; Newell DR; Lunec J; Wedge SR; Heightman TD
    Bioconjug Chem; 2018 Jun; 29(6):2100-2106. PubMed ID: 29851469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway.
    Cui Y; Zhou J; Rong F
    Biochem Biophys Res Commun; 2020 Dec; 533(4):665-671. PubMed ID: 33051060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactivation of p53 via MDM2 inhibition.
    Kim ES; Shohet JM
    Cell Death Dis; 2015 Oct; 6(10):e1936. PubMed ID: 26492369
    [No Abstract]   [Full Text] [Related]  

  • 28. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
    Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.
    Phelps D; Bondra K; Seum S; Chronowski C; Leasure J; Kurmasheva RT; Middleton S; Wang D; Mo X; Houghton PJ
    Pediatr Blood Cancer; 2015 Aug; 62(8):1345-52. PubMed ID: 25832557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.
    Glenn KJ; Yu LJ; Reddy MB; Fretland AJ; Parrott N; Hussain S; Palacios M; Vazvaei F; Zhi J; Tuerck D
    Xenobiotica; 2016 Aug; 46(8):667-76. PubMed ID: 26586447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoencapsulation of MDM2 Inhibitor RG7388 and Class-I HDAC Inhibitor Entinostat Enhances their Therapeutic Potential Through Synergistic Antitumor Effects and Reduction of Systemic Toxicity.
    Abed A; Greene MK; Alsa'd AA; Lees A; Hindley A; Longley DB; McDade SS; Scott CJ
    Mol Pharm; 2024 Mar; 21(3):1246-1255. PubMed ID: 38334409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach.
    Higgins B; Glenn K; Walz A; Tovar C; Filipovic Z; Hussain S; Lee E; Kolinsky K; Tannu S; Adames V; Garrido R; Linn M; Meille C; Heimbrook D; Vassilev L; Packman K
    Clin Cancer Res; 2014 Jul; 20(14):3742-52. PubMed ID: 24812409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.
    Fan X; Wang Y; Song J; Wu H; Yang M; Lu L; Weng X; Liu L; Nie G
    Cancer Biol Ther; 2019; 20(10):1328-1336. PubMed ID: 31311404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
    Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
    Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
    Van Maerken T; Speleman F; Vermeulen J; Lambertz I; De Clercq S; De Smet E; Yigit N; Coppens V; Philippé J; De Paepe A; Marine JC; Vandesompele J
    Cancer Res; 2006 Oct; 66(19):9646-55. PubMed ID: 17018622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma.
    Gomes S; Raimundo L; Soares J; Loureiro JB; Leão M; Ramos H; Monteiro MN; Lemos A; Moreira J; Pinto M; Chlapek P; Veselska R; Sousa E; Saraiva L
    Cancer Lett; 2019 Apr; 446():90-102. PubMed ID: 30664963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells.
    Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rathinavelu A
    Cells; 2018 Dec; 8(1):. PubMed ID: 30583560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.
    Zafar A; Wang W; Liu G; Xian W; McKeon F; Zhou J; Zhang R
    Cancer Lett; 2021 Jan; 496():16-29. PubMed ID: 33007410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
    Zhang Z; Ding Q; Liu JJ; Zhang J; Jiang N; Chu XJ; Bartkovitz D; Luk KC; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
    Bioorg Med Chem; 2014 Aug; 22(15):4001-9. PubMed ID: 24997575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.